A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Abemaciclib (Primary)
- Indications Brain metastases; Breast cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 14 Oct 2017 Planned number of patients changed from 247 to 251.
- 02 Jun 2017 Preliminary results of stage I safety and efficacy analysis, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 19 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History